These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12270592)

  • 41. Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage.
    Chermá MD; Josefsson M; Rydberg I; Woxler P; Trygg T; Hollertz O; Gustafsson PA
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):295-307. PubMed ID: 27220743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of chronic methylphenidate administration on operant test battery performance in juvenile rhesus monkeys.
    Rodriguez JS; Morris SM; Hotchkiss CE; Doerge DR; Allen RR; Mattison DR; Paule MG
    Neurotoxicol Teratol; 2010; 32(2):142-51. PubMed ID: 19737611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies.
    Krishnan S; Montcrief S
    Basic Clin Pharmacol Toxicol; 2007 Oct; 101(4):231-40. PubMed ID: 17845504
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
    Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
    J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs.
    Lavy E; Prise U; Soldani G; Neri D; Brandriss N; Bar Chaim A; Giorgi M
    Vet J; 2011 Sep; 189(3):336-40. PubMed ID: 20696604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methylphenidate as a reinforcer for rats: contingent delivery and intake escalation.
    Marusich JA; Beckmann JS; Gipson CD; Bardo MT
    Exp Clin Psychopharmacol; 2010 Jun; 18(3):257-66. PubMed ID: 20545390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Toxicology and carcinogenesis studies of 3,3',4,4'-tetrachloroazobenzene (TCAB) (CAS No. 14047-09-7) in Harlan Sprague-Dawley rats and B6C3F1 mice (gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2010 Nov; (558):1-206. PubMed ID: 21383777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of chronic treatment with methylphenidate on oxidative stress and inflammation in hippocampus of adult rats.
    Motaghinejad M; Motevalian M; Shabab B
    Neurosci Lett; 2016 Apr; 619():106-13. PubMed ID: 26687276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Toxicokinetic assessment of methylphenidate (Ritalin(R)) in a 13-week oral (gavage) toxicity study in rats using an enantiomeric liquid chromatography/tandem mass spectrometry assay.
    Bakhtiar R; Tse FL
    Rapid Commun Mass Spectrom; 2003; 17(18):2160-2. PubMed ID: 12955748
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Juvenile methylphenidate exposure and factors that influence incentive processing.
    Brenhouse HC; Napierata L; Kussmaul L; Leussis M; Andersen SL
    Dev Neurosci; 2009; 31(1-2):95-106. PubMed ID: 19372691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NTP Toxicology and Carcinogenesis Studies of Promethazine Hydrochloride (CAS No. 58-33-3) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Dec; 425():1-272. PubMed ID: 12616286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Object memory impairment at post-drug Day 15 but not at Day 1 after a regimen of repeated treatment with oral methylphenidate.
    Taukulis HK; Bigney EE; Fry MD; Hooper C
    Neurosci Lett; 2014 Apr; 566():252-6. PubMed ID: 24631430
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
    Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G
    Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum.
    Chase T; Carrey N; Soo E; Wilkinson M
    Neuroscience; 2007 Feb; 144(3):969-84. PubMed ID: 17156936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.
    Remschmidt H; Hoare P; Ettrich C; Rothenberger A; Santosh P; Schmidt M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE; Medori R
    Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):297-304. PubMed ID: 16220213
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate.
    Díez-Suárez A; Vallejo-Valdivielso M; Marín-Méndez JJ; de Castro-Manglano P; Soutullo CA
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):723-730. PubMed ID: 28817309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.